Semaglutide is administered as a once-weekly subcutaneous injection. The standard titration schedule increases the dose every 4 weeks to minimize gastrointestinal side effects.
Standard schedule: Week 1-4 at 0.25 mg, Week 5-8 at 0.5 mg, Week 9-12 at 1.0 mg, Week 13-16 at 1.7 mg, Week 17+ at 2.4 mg (maintenance). Each dose level is held for at least 4 weeks before considering escalation. The 0.25 mg starter dose is intended for tolerance only and is not therapeutic. Patients who tolerate well may reach maintenance at 16 weeks; patients who experience significant side effects may take longer or stay at a lower maintenance dose. Injection sites: abdomen, thigh, or upper arm — rotated weekly.
NexLife is structured around clinical best practices for semaglutide. The same flat-rate pricing applies across the entire titration schedule ($145/mo on the 12-month plan from 0.25 mg through 2.4 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.